Network pharmacology: curing causal mechanisms instead of treating symptoms.
Cristian Nogales, Zeinab M Mamdouh, Markus List...
https://pubmed.ncbi.nlm.nih.gov/34895945/Actively Recruiting
Led by Radboud University Medical Center · Updated on 2026-10-28
10
Participants Needed
1
Research Sites
8 weeks
Total Duration
This clinical trial focuses on patients with advanced thyroid cancer who have no remaining standard treatment options. It explores a personalized drug repurposing approach using network pharmacology, where drug combinations are selected based on the unique genetic profile of each patients tumor. The study aims to assess whether giving individualized drug combinations is feasible and to evaluate the safety and tumor control potential of these treatments. Participants undergo tumor molecular profiling to identify personalized treatment plans using approved drugs administered at authorized doses. This is a single-arm, phase Ib trial lasting about four months. The first month is dedicated to tumor examination and treatment selection, followed by three months of treatment where patients receive their personalized drug combinations. Treatment regimens vary depending on the tumor genetics of each patient. Throughout the treatment period, participants have regular check-ups including blood tests, scans, and questionnaires to monitor safety and evaluate how well the treatment controls tumor growth. The primary outcomes focus on feasibility and safety over 12 weeks, with preliminary efficacy also assessed. The trial is sponsored by Radboud University Medical Center and funded by the EU Horizon REPO4EU project.
CONDITIONS
Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
R
R Netea-Maier, Prof. Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Radboud University Medical Center
Lead Sponsor
Maastricht University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 month
Participants undergo tumor genetic profiling to identify personalized drug combinations. The best treatment plan is selected based on this information and agreed upon with the patient and their doctor.
Duration - 3 months
Participants receive personalized drug combinations tailored to their tumor profile. They are monitored closely with regular check-ups, blood tests, scans, and questionnaires to evaluate safety and tumor response.
Regular visits throughout treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Cristian Nogales, Zeinab M Mamdouh, Markus List...
https://pubmed.ncbi.nlm.nih.gov/34895945/Radboud University Medical Center
Lead Sponsor
Maastricht University
Collaborating Sponsor